Drug Trial Radar · NCT06205797
To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
Last checked: Nov 19, 2026Latest source record: Oct 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
312
Planned (sponsor's estimate)
Start
Jun 20, 2024
Primary completion
Nov 30, 2024
Study completion Mar 31, 2025
Sponsor
- Lead sponsor
- Huons BiopharmaIndustry
- Sponsor type
- Industry
- First posted
- Jan 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
Conditions
- Glabellar Lines
Interventions
HU-045Drug
HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use. White powder Other Names: IncobotulinumtoxinA
Xeomin®Drug
Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use. Other Names: IncobotulinumtoxinA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants whose glabellar lines at maximal frown are improvedTime frame: Week4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kangbuk Samsung Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.